Axogen Inc (AXGN) Stock Price, Quote & News

Company Profile

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wra...

Industry: Medical Devices

Sector: Healthcare

Phone: 386 462 6800

Fax: 386 462 6801

Website: www.axogeninc.com

Address:

13631 Progress Boulevard, Suite 400, Alachua, United States

dustin1101 Aug. 19 at 3:05 PM

$AXGN Just added 200 more 49.80. Been adding low 50s chunks. Super low vol nonsense to start the day.

2 · Reply

dustin1101 Aug. 19 at 1:25 PM

$AXGN Could be a big day today. Sector is bumping with MRNA news and mkt is green/bond rates easing on treasury action. GL shorts!

0 · Reply

dustin1101 Aug. 18 at 1:48 PM

$AXGN ATH 56.85 magnet... Once again bio/health proving to be the place to be when the mkt spooks. Congrats to those who had the patience on this 👏

0 · Reply

dustin1101 Aug. 14 at 2:12 PM

$AXGN could def prove me wrong. It does so from time to time... but I don't think the breakout run is done yet. Sector is a little skittish this morning, but there's just been so little sell volume. Since the break we've seen 20-30K blocks max. Wake me when you see 50-100K chunks hit the tape.

2 · Reply

TheMarketsTheTarget Aug. 13 at 7:42 PM

$AXGN Tough day - a tease

1 · Reply

dustin1101 Aug. 13 at 7:42 PM

$AXGN not worried about a little pullback on some post ER insider sales. Typical move for them. Added a couple hundred back under 48.

0 · Reply

dustin1101 Aug. 12 at 7:43 PM

$AXGN Coming up on $50 and 🦗🦗🦗

0 · Reply

dustin1101 Aug. 11 at 2:55 PM

$AXGN Updated short interest data to be reported today. I bet it's over 6M shares. Volume is still quite light. Tutes seem to be locked in and letting it rise on retail buying. I imagine if we see continuation, a bigger short report and 50+ that we'll see some intense covering volume come in. Aetna update any day is another wild card. GL!

1 · Reply

dustin1101 Aug. 10 at 2:47 PM

$AXGN queue the "after the move" posters.. Breaking out. Expect volume to increase as shorts begin to cover. $50+ on the way. $56.85 ATH magnet.

0 · Reply

dustin1101 Aug. 7 at 8:02 PM

$AXGN Beautiful end of week. Highest close since the ATH run over 5 years ago.

0 · Reply

AxoGen price target raised to $55 from $50 at Jefferies

2026-07-30T11:06:55.000Z - 20 days ago

AxoGen price target raised to $55 from $50 at Canaccord

2026-07-30T10:05:29.000Z - 20 days ago

AxoGen price target raised to $53 from $50 at H.C. Wainwright

2026-07-30T09:45:16.000Z - 20 days ago

AxoGen price target raised to $55 from $50 at Citizens

2026-07-29T18:35:42.000Z - 21 days ago

AxoGen price target raised to $55 from $50 at Jefferies

Jul 29, 2026, 8:00 AM EDT - 21 days ago

Axogen Earnings Call Transcript: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 21 days ago

Axogen Slides: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 21 days ago

Axogen Quarterly report: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 21 days ago

Axogen Earnings release: Q2 2026

2026-07-29T11:30:31.000Z - 21 days ago

AxoGen reports Q2 adjusted EPS 12c, consensus 12c

2026-07-29T11:30:18.000Z - 21 days ago

AxoGen raises FY26 revenue view to $279M from $270M, consensus $270.92M

2026-07-29T11:20:58.000Z - 21 days ago

Trace Biosciences announces strategic investment from Axogen

Jul 29, 2026, 7:05 AM EDT - 21 days ago

Axogen, Inc. Reports Second Quarter 2026 Financial Results

Jul 28, 2026, 9:00 AM EDT - 22 days ago

Axogen Slides: Corporate presentation

2026-07-20T20:15:49.000Z - 4 weeks ago

Neuronetics appoints Nir Naor as CFO, CLO Andrew Macan to step down

STIM

Jul 15, 2026, 7:00 AM EDT - 5 weeks ago

Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026

Jun 23, 2026, 8:30 AM EDT - 2 months ago

Axogen Transcript: AGM 2026

May 13, 2026, 12:35 PM EDT - 3 months ago

Axogen Transcript: Bank of America Global Healthcare Conference 2026

Apr 30, 2026, 7:00 AM EDT - 3 months ago

Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference

2026-04-29T16:57:39.000Z - 4 months ago

AxoGen price target raised to $48 from $41 at Raymond James

2026-04-29T13:02:40.000Z - 4 months ago

AxoGen price target raised to $50 from $45 at Canaccord

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Axogen Proxy statement: Proxy filing

2026-04-29T10:16:26.000Z - 4 months ago

AxoGen price target raised to $50 from $39 at H.C. Wainwright

2026-04-29T09:53:29.000Z - 4 months ago

AxoGen price target raised to $50 from $42 at Citizens

2026-04-28T14:28:46.000Z - 4 months ago

AxoGen rises 12.8%

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Axogen Earnings Call Transcript: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Axogen Earnings release: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Axogen Slides: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Axogen Quarterly report: Q1 2026

2026-04-28T11:49:44.000Z - 4 months ago

AxoGen raises FY26 revenue view to $270M from $265.7M, consensus $265.89M

2026-04-28T11:08:24.000Z - 4 months ago

AxoGen reports Q1 adjusted EPS 7c, consensus 7c

Apr 28, 2026, 7:00 AM EDT - 4 months ago

Axogen, Inc. Reports First Quarter 2026 Financial Results

2026-04-24T11:16:41.000Z - 4 months ago

AxoGen price target raised to $45 from $40 at Canaccord

2026-04-23T12:44:20.000Z - 4 months ago

AxoGen price target raised to $50 from $40 at Lake Street

2026-04-16T20:00:22.000Z - 4 months ago

AxoGen jumps after Cigna picks up Avance nerve graft

Apr 14, 2026, 7:00 AM EDT - 4 months ago

Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026

Mar 10, 2026, 12:30 PM EDT - 5 months ago

Axogen Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 1:00 PM EDT - 5 months ago

Axogen Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 6:00 AM EST - 6 months ago

Axogen Slides: Corporate presentation

Mar 3, 2026, 3:25 PM EST - 6 months ago

Axogen Transcript: 47th Annual Raymond James Institutional Investor Conference

Feb 24, 2026, 8:00 AM EST - 6 months ago

Axogen Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:00 AM EST - 6 months ago

Axogen Annual report: Q4 2025

Feb 24, 2026, 8:00 AM EST - 6 months ago

Axogen Earnings release: Q4 2025

Feb 24, 2026, 8:00 AM EST - 6 months ago

Axogen Slides: Q4 2025

2026-02-24T12:06:53.000Z - 6 months ago

AxoGen reports Q4 adjusted EPS 7c, consensus 10c

Feb 17, 2026, 7:00 AM EST - 6 months ago

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Feb 10, 2026, 7:00 AM EST - 6 months ago

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Jan 21, 2026, 11:18 PM EST - 7 months ago

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

Jan 21, 2026, 4:09 PM EST - 7 months ago

Axogen Announces Proposed Public Offering of Common Stock

Jan 15, 2026, 1:30 PM EST - 7 months ago

Axogen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 1:30 PM EST - 7 months ago

Axogen Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 7 months ago

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

Dec 3, 2025, 8:01 PM EST - 9 months ago

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

Dec 3, 2025, 6:53 PM EST - 9 months ago

FDA approves Axogen's nerve repair graft

Dec 2, 2025, 12:30 PM EST - 9 months ago

Axogen Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 11:30 AM EST - 9 months ago

Axogen Transcript: Jefferies London Healthcare Conference 2025

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Axogen Earnings Call Transcript: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Axogen Quarterly report: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Axogen Earnings release: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Axogen Slides: Q3 2025

Oct 29, 2025, 7:00 AM EDT - 10 months ago

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Oct 1, 2025, 12:30 PM EDT - 11 months ago

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

Aug 25, 2025, 6:40 AM EDT - 1 year ago

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Axogen Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Axogen Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Axogen Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Axogen Slides: Q2 2025

Jul 29, 2025, 4:10 PM EDT - 1 year ago

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 22, 2025, 4:05 PM EDT - 1 year ago

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

Jun 11, 2025, 2:00 PM EDT - 1 year ago

Axogen Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 1 year ago

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

Axogen Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Axogen Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Axogen Earnings release: Q1 2025

May 8, 2025, 7:05 AM EDT - 1 year ago

Axogen, Inc. Reports 2025 First Quarter Financial Results

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Axogen Proxy statement: Proxy Filing

Apr 24, 2025, 8:04 AM EDT - 1 year ago

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

Mar 4, 2025, 9:00 AM EST - 1 year ago

Axogen Transcript: Investor Day 2025

Mar 4, 2025, 9:00 AM EST - 1 year ago

Axogen Slides: FY 2025

Feb 25, 2025, 8:00 AM EST - 1 year ago

Axogen Earnings Call Transcript: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Axogen Annual report: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Axogen Earnings release: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Axogen Slides: Q4 2024

Feb 25, 2025, 7:10 AM EST - 1 year ago

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Feb 11, 2025, 4:58 PM EST - 1 year ago

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Jan 10, 2025, 5:00 PM EST - 1 year ago

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2024, 8:00 AM EST - 1 year ago

Axogen Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Axogen Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Axogen Earnings release: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Axogen Slides: Q3 2024

Sep 6, 2024, 7:00 AM EDT - 2 years ago

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Axogen Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Axogen Quarterly report: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Axogen Earnings release: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Axogen Slides: Q2 2024

Aug 8, 2024, 7:05 AM EDT - 2 years ago

Axogen, Inc. Announces New Leadership Appointments

Jul 23, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Jul 1, 2024, 7:00 AM EDT - 2 years ago

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jun 24, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

May 29, 2024, 4:40 PM EDT - 2 years ago

Axogen Transcript: 2024 Leerink Partners Healthcare Crossroads Conference

May 28, 2024, 4:30 PM EDT - 2 years ago

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

May 2, 2024, 8:00 AM EDT - 2 years ago

Axogen Earnings Call Transcript: Q1 2024

May 2, 2024, 8:00 AM EDT - 2 years ago

Axogen Quarterly report: Q1 2024

May 2, 2024, 8:00 AM EDT - 2 years ago

Axogen Earnings release: Q1 2024

May 2, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc Reports First Quarter 2024 Financial Results

Apr 29, 2024, 4:50 PM EDT - 2 years ago

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Axogen Proxy statement: Proxy Filing

Apr 16, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Axogen Proxy statement: Proxy Filing

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Axogen Registration statement: Registration Filing

Mar 6, 2024, 7:00 AM EST - 2 years ago

Axogen Registration statement: Registration Filing

Mar 5, 2024, 8:00 AM EST - 2 years ago

Axogen Earnings Call Transcript: Q4 2023

Mar 5, 2024, 8:00 AM EST - 2 years ago

Axogen Annual report: Q4 2023

Mar 5, 2024, 8:00 AM EST - 2 years ago

Axogen Earnings release: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Feb 13, 2024, 4:30 PM EST - 2 years ago

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Feb 2, 2024, 4:15 PM EST - 2 years ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jan 18, 2024, 5:00 PM EST - 2 years ago

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Jan 4, 2024, 4:45 PM EST - 2 years ago

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Jan 4, 2024, 4:40 PM EST - 2 years ago

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Jan 4, 2024, 4:35 PM EST - 2 years ago

Axogen Announces Promotions on Research and Development Team

Dec 26, 2023, 4:15 PM EST - 2 years ago

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Dec 6, 2023, 7:00 AM EST - 2 years ago

Axogen Announces Transition of Finance Team Leadership

Dec 1, 2023, 5:00 PM EST - 2 years ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 30, 2023, 8:50 AM EST - 2 years ago

Axogen Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 7, 2023, 8:00 AM EST - 3 years ago

Axogen Earnings Call Transcript: Q3 2023

Nov 7, 2023, 8:00 AM EST - 3 years ago

Axogen Quarterly report: Q3 2023

Nov 7, 2023, 8:00 AM EST - 3 years ago

Axogen Earnings release: Q3 2023

Nov 7, 2023, 8:00 AM EST - 3 years ago

Axogen Slides: Q3 2023

Nov 7, 2023, 7:00 AM EST - 3 years ago

Axogen, Inc. Reports 2023 Third Quarter Financial Results

Oct 18, 2023, 7:00 AM EDT - 3 years ago

Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023

Sep 5, 2023, 7:00 AM EDT - 3 years ago

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™

Aug 31, 2023, 7:00 AM EDT - 3 years ago

Axogen to Participate at Upcoming Investor Conferences

Aug 21, 2023, 7:00 AM EDT - 3 years ago

Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio

dustin1101 Aug. 19 at 3:05 PM

$AXGN Just added 200 more 49.80. Been adding low 50s chunks. Super low vol nonsense to start the day.

2 · Reply

dustin1101 Aug. 19 at 1:25 PM

$AXGN Could be a big day today. Sector is bumping with MRNA news and mkt is green/bond rates easing on treasury action. GL shorts!

0 · Reply

dustin1101 Aug. 18 at 1:48 PM

$AXGN ATH 56.85 magnet... Once again bio/health proving to be the place to be when the mkt spooks. Congrats to those who had the patience on this 👏

0 · Reply

dustin1101 Aug. 14 at 2:12 PM

2 · Reply

TheMarketsTheTarget Aug. 13 at 7:42 PM

$AXGN Tough day - a tease

1 · Reply

dustin1101 Aug. 13 at 7:42 PM

$AXGN not worried about a little pullback on some post ER insider sales. Typical move for them. Added a couple hundred back under 48.

0 · Reply

dustin1101 Aug. 12 at 7:43 PM

$AXGN Coming up on $50 and 🦗🦗🦗

0 · Reply

dustin1101 Aug. 11 at 2:55 PM

1 · Reply

dustin1101 Aug. 10 at 2:47 PM

$AXGN queue the "after the move" posters.. Breaking out. Expect volume to increase as shorts begin to cover. $50+ on the way. $56.85 ATH magnet.

0 · Reply

dustin1101 Aug. 7 at 8:02 PM

$AXGN Beautiful end of week. Highest close since the ATH run over 5 years ago.

0 · Reply

dustin1101 Aug. 7 at 5:26 PM

$AXGN Dwindling volume in this flag, looking good. Won’t take much to move this but will need volume through 46-47 if it’s going to finally break.

1 · Reply

dustin1101 Aug. 6 at 4:54 PM

$AXGN added 300 @ 44.31

0 · Reply

dustin1101 Aug. 6 at 2:11 PM

$XBI is on the move again.. $AXGN following suit toward 52wk high and breakout >> All time high could be a magnet.

0 · Reply

dustin1101 Aug. 5 at 1:53 PM

$AXGN $1.50 lower on 25K... sureee why not

0 · Reply

LuckEtradER Aug. 4 at 8:14 PM

$AXGN what a beast

0 · Reply

dustin1101 Aug. 4 at 7:02 PM

$AXGN big breakout potential...

0 · Reply

dustin1101 Aug. 4 at 3:34 PM

$AXGN Hey mr split order seller showing 600, 700 chunks via ARCA/BATS.. You know you could probably be selling these over $46 with the mkt today right? But you insist on dumping the bid 🤡

1 · Reply

dustin1101 Aug. 4 at 1:46 PM

$AXGN keep dipping it I'll buy back some more...

0 · Reply

dustin1101 Aug. 3 at 3:19 PM

$AXGN the writing is on the wall, it says "shorts are cooked" 🤑

0 · Reply

dustin1101 Aug. 3 at 2:36 PM

$AXGN keep an eye on this.. If Aetna covers Avance in the imminent update and we're at ~45... rocket squeeze to $50 to start IMO. https://www.aetna.com/cpb/medical/data/400_499/0416.html#dummyLink4

0 · Reply

newsofthemarket Aug. 3 at 2:23 PM

$AXGN Someone always knows something Someone is buying at any price while sellers are very low Some buy out or major news coming? 45 now, 6.68% up

1 · Reply

Tekoa Aug. 3 at 2:07 PM

$AXGN Good fundamentals combined with high institutional ownership and 11.85% short interest are a great combination. Best to all!

1 · Reply

Market Cap	2.64B
Revenue (ttm)	225.21M
Net Income (ttm)	-15.70M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6.97%
Debt to Equity Ratio	0.00

Volume	565,494
Avg Vol	1,325,230
Day's Range	N/A - N/A
Shares Out	53.76M
Stochastic %K	93%
Beta	1.11
Analysts	Strong Sell
Price Target	$52.67